Skip to main content
SpringerLink
Log in

Oncology—Lungs

  • Chapter
Clinical PET and PET/CT

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 99.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Bibliography

  1. Ahuja V, Coleman RE, Herndon J, Patz EF, Jr. The prognostic significance of fluorodeoxyglucose positron emission tomography imaging for patients with nonsmall cell lung carcinoma. Cancer 1998; 83(5):918–24.

    Article  PubMed  CAS  Google Scholar 

  2. Belhocine T, Foidart J, Rigo P, et al. Fluorodeoxyglucose positron emission tomography and somatostatin receptor scintigraphy for diagnosing and staging carcinoid tumours: correlations with the pathological indexes p53 and Ki-67. Nucl Med Commun 2002; 23(8):727–34.

    Article  PubMed  CAS  Google Scholar 

  3. Boiselle PM, Ernst A, Karp DD. Lung cancer detection in the 21st century: potential contributions and challenges of emerging technologies. AJR Am J Roentgenol 2000; 175(5):1215–21.

    PubMed  CAS  Google Scholar 

  4. Buck AK, Halter G, Schirrmeister H, et al. Imaging Proliferation in Lung Tumors with PET: (18)F-FLT Versus (18)F-FDG. J Nucl Med 2003; 44(9):1426–31.

    PubMed  CAS  Google Scholar 

  5. Coleman RE, Laymon CM, Turkington TG. FDG imaging of lung nodules: a phantom study comparing SPECT, camera-based PET, and dedicated PET. Radiology 1999; 210(3):823–8.

    PubMed  CAS  Google Scholar 

  6. Dizendorf EV, Baumert BG, von Schulthess GK, et al. Impact of whole-body 18F-FDG PET on staging and managing patients for radiation therapy. J Nucl Med 2003; 44(1):24–9.

    PubMed  Google Scholar 

  7. Duhaylongsod FG, Lowe VJ, Patz EF, Jr., et al. Lung tumor growth correlates with glucose metabolism measured by fluoride-18 fluorodeoxyglucose positron emission tomography. Ann Thorac Surg 1995; 60(5):1348–52.

    Article  PubMed  CAS  Google Scholar 

  8. Gambhir SS, Hoh CK, Phelps ME, et al. Decision tree sensitivity analysis for cost effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma. J Nucl Med 1996; 37(9):1428–36.

    PubMed  CAS  Google Scholar 

  9. Gould MK, Maclean CC, Kuschner WG, et al. Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. Jama 2001; 285(7):914–24.

    Article  PubMed  CAS  Google Scholar 

  10. Gould MK, Sanders GD, Barnett PG, et al. Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med 2003; 138(9):724–35.

    PubMed  Google Scholar 

  11. Hauber HP, Bohuslavizki KH, Lund CH, et al. Positron emission tomography in the staging of small-cell lung cancer: a preliminary study. Chest 2001; 119(3):950–4.

    Article  PubMed  CAS  Google Scholar 

  12. Heyneman LE, Patz EF. PET imaging in patients with bronchioloalveolar cell carcinoma. Lung Cancer 2002; 38(3):261–6.

    Article  PubMed  Google Scholar 

  13. Hicks RJ, Kalff V, MacManus MP, et al. The utility of (18)F-FDG PET for suspected recurrent non-small cell lung cancer after potentially curative therapy: impact on management and prognostic stratification. J Nucl Med 2001; 42(11):1605–13.

    PubMed  CAS  Google Scholar 

  14. Higashi K, Ueda Y, Arisaka Y, et al. 18F-FDG uptake as a biologic prognostic factor for recurrence in patients with surgically resected non-small cell lung cancer. J Nucl Med 2002; 43(1):39–45.

    PubMed  Google Scholar 

  15. Hoekstra CJ, Hoekstra OS, Stroobants SG, et al. Methods to monitor response to chemotherapy in non-small cell lung cancer with 18F-FDG PET. J Nucl Med 2002; 43(10):1304–9.

    PubMed  CAS  Google Scholar 

  16. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med 1997; 38(9):1382–3.

    PubMed  CAS  Google Scholar 

  17. Jemal A, Murray T, Samuels A, et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53(1):5–26.

    Article  PubMed  Google Scholar 

  18. Jeong HJ, Min JJ, Park JM, et al. Determination of the prognostic value of [(18)F]fluorodeoxyglucose uptake by using positron emission tomography in patients with non-small cell lung cancer. Nucl Med Commun 2002; 23(9):865–70.

    Article  PubMed  CAS  Google Scholar 

  19. Kalff V, Hicks RJ, MacManus MP, et al. Clinical impact of (18)F fluorodeoxyglucose positron emission tomography in patients with non-small-cell lung cancer: a prospective study. J Clin Oncol 2001; 19(1):111–8.

    PubMed  CAS  Google Scholar 

  20. Kamel EM, Zwahlen D, Wyss MT, et al. Whole-Body (18)F-FDG PET Improves the Management of Patients with Small Cell Lung Cancer. J Nucl Med 2003; 44(12):1911–7.

    PubMed  Google Scholar 

  21. Lardinois D, Weder W, Hany TF, et al. Staging of non-small cell lung cancer with integrated positron-emission tomography and computed tomography. New Engl J Med 2003; 348:2500–7.

    Article  PubMed  Google Scholar 

  22. Miyaoka RS, Kohlmyer SG, Lewellen TK. Hot sphere detection limits for a dual head coincidence imaging system. IEEE Trans Nucl Sci 1999; 46(6):2185–2191.

    Article  Google Scholar 

  23. Mountain CF, Dresler CM. Regional lymph node classification for lung cancer staging. Chest 1997; 111(6):1718–23.

    PubMed  CAS  Google Scholar 

  24. Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111(6):1710–7.

    PubMed  CAS  Google Scholar 

  25. Nestle U, Hellwig D, Fleckenstein J, et al. Comparison of early pulmonary changes in 18FDG-PET and CT after combined radiochemotherapy for advanced non-small-cell lung cancer: a study in 15 patients. Front Radiat Ther Oncol 2002; 37:26–33.

    PubMed  Google Scholar 

  26. Nestle U, Hellwig D, Schmidt S, et al. 2-Deoxy-2-[18F]fluoro-D-glucose positron emission tomography in target volume definition for radiotherapy of patients with non-small-cell lung cancer. Mol Imaging Biol 2002; 4(3):257–63.

    PubMed  Google Scholar 

  27. Pandit N, Gonen M, Krug L, Larson SM. Prognostic value of [18F]FDG-PET imaging in small cell lung cancer. Eur J Nucl Med Mol Imaging 2003; 30(1):78–84.

    Article  PubMed  Google Scholar 

  28. Patz EF, Jr., Connolly J, Herndon J. Prognostic value of thoracic FDG PET imaging after treatment for non-small cell lung cancer. AJR Am J Roentgenol 2000; 174(3):769–74.

    PubMed  Google Scholar 

  29. Seltzer MA, Yap CS, Silverman DH, et al. The impact of PET on the management of lung cancer: the referring physician’s perspective. J Nucl Med 2002; 43(6):752–6.

    PubMed  Google Scholar 

  30. Simon GR, Wagner H. Small cell lung cancer. Chest 2003; 123(1 Suppl):259S–271S.

    PubMed  Google Scholar 

  31. Vansteenkiste JF, Stroobants SG, Dupont PJ, et al. Prognostic importance of the standardized uptake value on (18)F-fluoro-2-deoxy-glucose-positron emission tomography scan in non-small-cell lung cancer: An analysis of 125 cases. Leuven Lung Cancer Group. J Clin Oncol 1999; 17(10):3201–6.

    PubMed  CAS  Google Scholar 

  32. Weber W, Young C, Abdel-Dayem HM, et al. Assessment of pulmonary lesions with 18F-fluorodeoxyglucose positron imaging using coincidence mode gamma cameras. J Nucl Med 1999; 40(4):574–8.

    PubMed  CAS  Google Scholar 

  33. Weber WA, Petersen V, Schmidt B, et al. Positron emission tomography in non-small-cell lung cancer: prediction of response to chemotherapy by quantitative assessment of glucose use. J Clin Oncol 2003; 21(14):2651–7.

    Article  PubMed  CAS  Google Scholar 

  34. Weir HK, Thun MJ, Hankey BF, et al. Annual report to the nation on the status of cancer, 1975–2000, featuring the uses of surveillance data for cancer prevention and control. J Natl Cancer Inst 2003; 95(17):1276–99.

    PubMed  Google Scholar 

  35. Yap CS, Schiepers C, Fishbein MC, et al. FDG-PET imaging in lung cancer: how sensitive is it for bronchioloalveolar carcinoma? Eur J Nucl Med Mol Imaging 2002; 29(9):1166–73.

    Article  PubMed  CAS  Google Scholar 

Download references

Rights and permissions

Reprints and permissions

Copyright information

© 2005 Springer-Verlag London Limited

About this chapter

Cite this chapter

(2005). Oncology—Lungs. In: Clinical PET and PET/CT. Springer, London. https://doi.org/10.1007/1-84628-100-8_7

Download citation

  • DOI: https://doi.org/10.1007/1-84628-100-8_7

  • Publisher Name: Springer, London

  • Print ISBN: 978-1-85233-838-1

  • Online ISBN: 978-1-84628-100-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation